Last reviewed · How we verify

NCT06322511: DFG II

Dialogical Family Guidance PostDoc Study

Recruiting now NA Last updated 21 March 2024
What this trial tests

NA trial testing Dialogical Family Guidance (DFG) in Family Dynamics in 50 participants. Currently enrolling.

Timeline
2 January 2024
Primary endpoint
31 December 2027
31 December 2027

Quick facts

Lead sponsorTampere University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingdouble
Primary purposesupportive care
Enrollment50
Start date2 January 2024
Primary completion31 December 2027
Estimated completion31 December 2027
Sites1 location across Finland

Drugs / interventions tested

Conditions studied

Sponsor

Tampere University

Who can join

Adults 4 to 13, any sex, with Family Dynamics or Family Relations. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This new family intervention, called Dialogical Family Guidance (DFG) is developed to target family needs especially in families with a child with neurodevelopmental disorders. PhD study showed, that this intervention is functioning with this target group. Participants (families) experienced that they got information, guidance to ordinary life and that the DFG-therapists were listening to them and above all, helping with individual problems and questions. DFG include six meetings and professionals need to attend on a 3-day long education before using this intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Family Dynamics

Currently open trials in the same condition.

Other Tampere University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06322511.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing